Date:12.May.2022
Your Name:Yuya Hagiwara
Manuscript Title: Risk factors for early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-
bound paclitaxel combined with ramucirumab in advanced gastric cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
4.5			
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests	INUTIE	
	maneiar micrests		
Ple	Please summarize the above conflict of interest in the following box:		

The authors has nothing to disclose.	

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_12. May.2022
our Name: Akio Nakasya
Manuscript Title:_Risk factors for early-onset severe neutropenia due to paclitaxel or nanoparticle albumin
oound paclitaxel combined with ramucirumab in advanced gastric cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	,		
7	Support for attending	None	
	meetings and/or travel		
	meetings and or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Pla	ease summarize the above o	onflict of interest in the	following hox:
	ase sammanze the above c		Tollowing Son.
	The authors has nothing to dis	rlose	

The authors has nothing to disclose.	

\_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:13/May/2022
Your Name:Toshihiko Matsumoto
Manuscript Title:_Risk factors for early-onset severe neutropenia due to paclitaxel or nanoparticle album
bound paclitaxel combined with ramucirumab in advanced gastric cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	None	
	lectures, presentations,	Daiichi-Sankyo Pharma	
	speakers bureaus,	Ono pharma	
	manuscript writing or	Bristol Myers Squibb	
	educational events	Eily Lilly	
		Takeda Pharma	
		Chugai pharma	
		Mercke Serono pharma	
		Taiho pharma	
		Yakulut Honsya	
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

# Please summarize the above conflict of interest in the following box:

Toshihiko Matsumoto received honoraria for lectures from Chugai Pharmaceutical, Takeda Pharmaceutical, Yakult-Honsha, Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo Pharmaceutical, Bristol Myers Squibb, Eily Lilly Japan, and Merck Serano Pharmaceutical.

Please place an "X" next to the following statement to indicate your agreement:			
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:13/May/2022
Your Name:Tatsuki Ikoma
Manuscript Title:_Risk factors for early-onset severe neutropenia due to paclitaxel or nanoparticle albumir
bound paclitaxel combined with ramucirumab in advanced gastric cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		I	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	ivo time initi for this term.		
		Time frame: past	26 months
2	Grants or contracts from	X None	30 months
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	XNone		
	meetings and/or travel			
8	Datants planned issued or	X None		
٥	Patents planned, issued or pending	xnone		
	pending			
•	5 5 .	V N		
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	•	V None		
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
11	Stock of Stock options			
12	Receipt of equipment,	X None		
12	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	X None		
	financial interests			
Please summarize the above conflict of interest in the following box:				
	reade dammanize the above commet of interest in the following box.			

The authors has nothing to disclose.	

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 19, May, 2022	
Your Name:Yoshiyul	i Yamamoto
Manuscript Title:_Risk f	actors for early-onset severe neutropenia due to paclitaxel or nanoparticle albumin
bound paclitaxel com	pined with ramucirumab in advanced gastric cancer_
Manuscript number (if k	nown):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	-
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for	Sanofi, Nihon Kayaku,	
	lectures, presentations,	Eisai, Bayer, Lilly, Taiho,	
	speakers bureaus,	Daiichi Sankyo, Yakult,	
	manuscript writing or	Nihon Servier, Asahi Kasei	
	educational events	Parma., and Ono	
6	Payment for expert	None	
	testimony		
	-		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	4	
11	Stock or stock options	None	
12	Receipt of equipment,	✓ None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	_ <b>✓</b> None	
	financial interests		
Plea	Please summarize the above conflict of interest in the following box:		

Daiichi Sankyo, Yakult, Nihon Servier, Asahi Kasei Parma., and Ono.	Kayaku, Eisai, Bayer, Lilly, Taiho,

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_	19/May/2022	
Your N	lame: Yusuke Kurioka	
Manus	script Title:_Risk factors for early-onset severe neutropenia due to paclitaxel or nanopartic	le albumin
bound	d paclitaxel combined with ramucirumab in advanced gastric cancer_	
Manus	script number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
4.0			
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests	_^NOTIE	
	maneral micresis		
Ple	ease summarize the above o	onflict of interest in the fo	llowing box:

The authors has no	The authors has nothing to disclose.			

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	None		
	testimony			
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	None		
	in other board, society,			
	committee or advocacy			
4 :	group, paid or unpaid			
11	Stock or stock options	None		
12	Descint of anylogopat	Nana		
12	Receipt of equipment, materials, drugs, medical	None		
	writing, gifts or other			
	services			
13	Other financial or non-	None		
13	financial interests			
	a. interests			
Ple	Please summarize the above conflict of interest in the following box:			

The authors has nothing to disclose.		

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_12/May/2022	
Your Name:_Takeshi Kajiwara	
Manuscript Title:_Risk factors for early-onset severe neutropenia due to paclitaxel or nanoparticle	albumin
bound paclitaxel combined with ramucirumab in advanced gastric cancer_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None Taiho Pharmaceutical Co., Ltd.	Personal
	manuscript writing or educational events	Chugai Pharmaceutical Co., Ltd.	Personal
		Ono Pharmaceutical Co., Ltd.	Personal
		Eli Lilly Japan K.K.	Personal
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
	-		
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

## Please summarize the above conflict of interest in the following box:

Takeshi Kajiwara received honoraria for lectures from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co.,
Ltd., Ono Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:13/May/2022	
Your Name:Tomohiro Nishina	
Manuscript Title:_Risk factors for early-onset severe neutropenia due to paclitaxel or nanoparticle all	bumin
bound paclitaxel combined with ramucirumab in advanced gastric cancer_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Daiichi-Sankyo Pharma Ono pharma Bristol Myers Squibb Eily Lilly Takeda Pharma Chugai pharma Mercke Serono pharma Taiho pharma Yakulut Honsya	Lectures
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Janssen Pharmaceutical	Data Safety Monitoring Board
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

## Please summarize the above conflict of interest in the following box:

Tomohiro Nishina received honoraria for lectures from Chugai Pharmaceutical, Takeda Pharmaceutical, Yakult-Honsha, Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo Pharmaceutical, Bristol Myers Squibb, Eily Lilly Japan, and Merck Serano, Pharmaceutical and a Data Safety Monitoring Board member from Janssen Pharmaceutical.

Please place an "X" next to the following statement to indicate your agreement:		
X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:13/May/2022	
Your Name:Natsumi Yamashita	
Manuscript Title:_Risk factors for early-onset severe neutropenia due to paclitaxel or nanopartic	cle albumin-
bound paclitaxel combined with ramucirumab in advanced gastric cancer_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_XNone	
4	Consulting fees	X_None	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_XNone		
	testimony			
7	Support for attending meetings and/or travel	_XNone		
8	Patents planned, issued or	X_None		
	pending			
9	Participation on a Data	_XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_XNone		
12	Descint of anxious aut	V Mana		
12	Receipt of equipment, materials, drugs, medical	_X_None		
	writing, gifts or other			
	services			
13	Other financial or non-	X None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			

Natsumi Yamashita has nothing to disclose.	

\_ X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:12/May/2022
Your Name:Toshikazu Moriwaki
Manuscript Title:_Risk factors for early-onset severe neutropenia due to paclitaxel or nanoparticle albumir
bound paclitaxel combined with ramucirumab in advanced gastric cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time innit for this item.		
		Time frame: past	26 months
2	Grants or contracts from	None None	
_	any entity (if not indicated	Taiho Pharmaceutical	Institution
	in item #1 above).	Tamo i narmaceatica	Institution
3	Royalties or licenses	X None	
4	Consulting fees	_XNone	

			<del>-</del>	
5	Payment or honoraria for	None		
	lectures, presentations,	Eli Lilly	speakers bureaus	
	speakers bureaus,	Taiho Pharmaceutical	speakers bureaus	
	manuscript writing or educational events	Bristol-Myers Squibb	speakers bureaus	
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
_				
9	Participation on a Data	_XNone		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	X None		
10	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	_XNone		
	financial interests			
Pla	Please summarize the above conflict of interest in the following hox:			

Toshikazu Moriwaki reports speakers bureaus from Eli Lilly, Taiho Pharmaceutical, and Brisgrant from Taiho Pharmaceutical outside the submitted work.	tol-Myers Squibb, and a

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	3/May/2022	
Your Name:	Ichinosuke Hyodo	
<b>Manuscript Titl</b>	Risk factors for early-onset severe neutropenia due to paclitaxel or nanoparticle albumi	n
bound paclita	l combined with ramucirumab in advanced gastric cancer_	
Manuscript nur	per (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial pl	anning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	xNone	
		Time frame: past 36	months
2	Grants or contracts from any entity (if not indicated in item #1 above).	x_None	
3	Royalties or licenses	xNone	
4	Consulting fees		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert	Chugai Pharmaceutical, Takeda Pharmaceutical Yakult-Honsha	Lectures
0	testimony	x_None	
7	Support for attending meetings and/or travel	x_None	
8	Patents planned, issued or pending	x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Asahi-Kasei Pharmaceutical Chugai Pharmaceutical Taiho Pharmaceutical Ono Pharmaceutical Daiichi-Sankyo Pharmaceutical Merck Serano Pharmaceutical	Advisory Board  Data Safety Monitoring Board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	xNone	
11	Stock or stock options	xNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	xNone	
13	Other financial or non- financial interests	xNone	

## Please summarize the above conflict of interest in the following box:

Ichinosuke Hyodo received honoraria for lectures from Chugai Pharmaceutical, Takeda Pharmaceutical, and Yakult-Honsha, and payment as an Advisory Board member from Asahi-Kasei Pharmaceutical and a Data Safety Monitoring Board member from Chugai Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo Pharmaceutical, and Merck Serano Pharmaceutical.

Please place an "X" next to the following statement to indicate your agreement:
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.